Hank Kucheman, Boston Scientific Interim CEO, and Michael Mahoney, Boston Scientific Icoming CEO, shed insight on a pro-longed CEO transition and pricing pressures in the device industry. Remember that Mahoney was the Group Chairman of J&J’s Medical Device and Diagnostics business until Boston Scientific recruited him away earlier this year. BSCI and J&J wrangled over that transition but ultimately agreed on a compromise that mandated the lengthy transition that Mahoney must now endure to take over the lead role at Boston Scientific.
He laid out his plans for bringing BSCI back to prominence at last week’s JPMorgan Healthcare conference with the strategy focused mostly on new products and emerging markets for the company.
